Alpha Cognition(ACOG.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Alpha Cognition
ACOG.US
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
1.955 T
ACOG.USMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking137/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-125.65%E
    • Profit Margin-262.18%E
    • Gross Margin77.89%A
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY-32.36%D
    • Total Assets YoY820.85%A
    • Net Assets YoY1261.58%A
  • Cash ScoreD
    • Cash Flow Margin-38.14%D
    • OCF YoY0.00%C
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreB
    • Gearing Ratio26.75%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alpha Cognition Grants Equity Awards to Executive Team Under 2025 Incentive Plan

    Alpha Cognition Inc. has granted new equity awards to its executive team under the 2025 Stock and Incentive Plan. CEO Michael McFadden received 190,549 RSUs and 177,576 stock options, both vesting over three years, plus performance share units based on stock price. COO Lauren D’Angelo was awarded 137,195 RSUs and 106,545 stock options, while Interim CFO Henry Du received 20,579 RSUs and 15,982 stock options, all with similar vesting schedules. This announcement is for informational purposes only and not financial advice.

    Reuters·
    US
    ACOG
    -2.56%
    Reuters·
    US
    ACOG
    -2.56%

    Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution | ACOG Stock News

    Alpha Cognition, Inc. (NASDAQ: ACOG) provided a corporate update outlining its strategic priorities for 2026, focusing on expanding the prescriber base for ZUNVEYL to 2,000 healthcare providers and increasing nursing home penetration. The company plans to complete three studies in 2026 to support ZUNVEYL's impact on Alzheimer's patients. Alpha Cognition aims for operating profitability by 2027, with significant commercial efforts and potential licensing agreements in Asia. Highlights from 2025 include the initiation of ZUNVEYL commercialization and securing a $44 million licensing agreement for development in Asia.

    StockTitan·
    US
    ACOG
    -2.56%
    StockTitan·
    US
    ACOG
    -2.56%

    Alpha Cognition CEO Joins Titan Partners Virtual Fireside Chat

    Alpha Cognition Inc.'s CEO, Michael McFadden, will join a virtual fireside chat hosted by Titan Partners on December 2, 2025. The discussion will focus on the company's commercialization efforts and research initiatives for neurodegenerative disease therapies. This event is informational and not financial advice.

    Reuters·
    US
    ACOG
    -2.56%
    Reuters·
    US
    ACOG
    -2.56%

    Alpha Cognition’s Earnings Call: Strong Sales and Strategic Growth

    Alpha Cognition Inc. reported strong Q3 2025 results, driven by a 44% increase in ZUNVEYL sales and significant market engagement. The company engaged with 2,038 long-term care homes, with 70% placing repeat orders. Despite an operating loss of $5.3 million, Alpha Cognition's financial health is bolstered by $38 million in equity proceeds, extending its operational runway into 2027. Challenges include high operating expenses and limited payer coverage. The company plans to initiate two studies, CONVERGE and BEACON, to further assess ZUNVEYL’s benefits, with completion expected by late 2026.

    Tip Ranks·
    US
    ACOG
    -2.56%
    Tip Ranks·
    US
    ACOG
    -2.56%

    Alpha Cognition Inc. reports $2.8 million revenue in Q3 2025 with 102% growth in pharmacy orders

    Alpha Cognition Inc. reported Q3 2025 revenues of $2.8 million, with a 102% increase in pharmacy orders. Product sales were $2.3 million, and business development revenue was $0.5 million. Operating loss was $5.3 million, and net loss improved to $1.3 million. Cash reserves totaled $73.2 million after October fundraising. The company anticipates operating profitability by 2027 and maintained 2025 spending guidance. The prescriber base expanded significantly.

    Reuters·
    US
    ACOG
    -2.56%
    Reuters·
    US
    ACOG
    -2.56%
    © 2026 Longbridge｜Disclaimer